Clarivate (CLVT)
Market Price (7/2/2026): $2.22 | Market Cap: $1.4 BilSector: Information Technology | Industry: IT Consulting & Other Services
Clarivate (CLVT)
Market Price (7/2/2026): $2.22Market Cap: $1.4 BilSector: Information TechnologyIndustry: IT Consulting & Other Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35% Attractive yieldFCF Yield is 23% Megatrend and thematic driversMegatrends include Artificial Intelligence, Precision Medicine, and Digital Health & Telemedicine. Themes include AI Software Platforms, Show more. | Weak multi-year price returns2Y Excs Rtn is -98%, 3Y Excs Rtn is -148% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.46 | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 288% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.3%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.3%, Rev Chg QQuarterly Revenue Change % is -1.4% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14% Key risksCLVT key risks include [1] a substantial debt burden and associated liquidity concerns, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35% |
| Attractive yieldFCF Yield is 23% |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, Precision Medicine, and Digital Health & Telemedicine. Themes include AI Software Platforms, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -98%, 3Y Excs Rtn is -148% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.46 |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 288% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.3%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.3%, Rev Chg QQuarterly Revenue Change % is -1.4% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14% |
| Key risksCLVT key risks include [1] a substantial debt burden and associated liquidity concerns, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/1/2026
Clarivate (CLVT) stock has lost about 10% since 3/31/2026 because of the following key factors:
1. Total revenue decline despite exceeding estimates. Clarivate reported total revenue of $585.5 million for fiscal Q1 2026 (the quarter ending March 31, 2026), which was a 1.4% decrease year-over-year, mainly attributed to inorganic disposals. While this figure surpassed analyst estimates of $569.50 million, and organic revenue did see a modest increase of 0.6%, the overall top-line contraction likely fostered investor apprehension regarding the company's revenue trajectory. The stock experienced a decline of 1.54% in the trading session immediately following the earnings release, despite the beat.
2. Persistent concerns regarding market share loss and long-term growth. Analysts continue to highlight that Clarivate is losing market share in some key markets due to prior underinvestment, which has allowed competitors to gain ground. This underlying structural concern about the company's competitive positioning and future growth prospects likely overshadowed the otherwise positive fiscal Q1 2026 earnings, contributing to the stock's negative trend.
Show more
Clarivate (CLVT) stock has lost about 10% since 3/31/2026 because of the following key factors:
1. Total revenue decline despite exceeding estimates. Clarivate reported total revenue of $585.5 million for fiscal Q1 2026 (the quarter ending March 31, 2026), which was a 1.4% decrease year-over-year, mainly attributed to inorganic disposals. While this figure surpassed analyst estimates of $569.50 million, and organic revenue did see a modest increase of 0.6%, the overall top-line contraction likely fostered investor apprehension regarding the company's revenue trajectory. The stock experienced a decline of 1.54% in the trading session immediately following the earnings release, despite the beat.
2. Persistent concerns regarding market share loss and long-term growth. Analysts continue to highlight that Clarivate is losing market share in some key markets due to prior underinvestment, which has allowed competitors to gain ground. This underlying structural concern about the company's competitive positioning and future growth prospects likely overshadowed the otherwise positive fiscal Q1 2026 earnings, contributing to the stock's negative trend.
Show more
Updated on 7/1/2026
Clarivate (CLVT) stock has lost about 10% since 3/31/2026 because of the following key factors:
1. Total revenue decline despite exceeding estimates. Clarivate reported total revenue of $585.5 million for fiscal Q1 2026 (the quarter ending March 31, 2026), which was a 1.4% decrease year-over-year, mainly attributed to inorganic disposals. While this figure surpassed analyst estimates of $569.50 million, and organic revenue did see a modest increase of 0.6%, the overall top-line contraction likely fostered investor apprehension regarding the company's revenue trajectory. The stock experienced a decline of 1.54% in the trading session immediately following the earnings release, despite the beat.
2. Persistent concerns regarding market share loss and long-term growth. Analysts continue to highlight that Clarivate is losing market share in some key markets due to prior underinvestment, which has allowed competitors to gain ground. This underlying structural concern about the company's competitive positioning and future growth prospects likely overshadowed the otherwise positive fiscal Q1 2026 earnings, contributing to the stock's negative trend.
3. High debt load remains a significant investor concern. As of the end of fiscal Q1 2026, Clarivate's total debt outstanding stood at a substantial $4.33 billion. Although the company demonstrated proactive debt management by retiring $143 million of debt during the quarter, supported by $78.9 million in free cash flow, the significant remaining leverage was noted by an equity research analyst as "still high". This elevated debt level could be a deterrent for investors, limiting confidence in the stock.
4. Predominantly cautious to negative analyst sentiment. As of July 1, 2026, Wall Street analysts generally maintained a "Hold" or "Reduce" consensus rating for Clarivate. Out of 8 analysts, 3 had a "Sell" rating, reflecting a cautious outlook for the stock's future performance. This prevailing sentiment among financial professionals likely contributed to downward pressure on the stock price, as the average price target of $3.22, while above the July 1, 2026 price of $2.22, suggests limited conviction for a strong rebound.
Show less
Clarivate (CLVT) stock has lost about 10% since 3/31/2026 because of the following key factors:
1. Total revenue decline despite exceeding estimates. Clarivate reported total revenue of $585.5 million for fiscal Q1 2026 (the quarter ending March 31, 2026), which was a 1.4% decrease year-over-year, mainly attributed to inorganic disposals. While this figure surpassed analyst estimates of $569.50 million, and organic revenue did see a modest increase of 0.6%, the overall top-line contraction likely fostered investor apprehension regarding the company's revenue trajectory. The stock experienced a decline of 1.54% in the trading session immediately following the earnings release, despite the beat.
2. Persistent concerns regarding market share loss and long-term growth. Analysts continue to highlight that Clarivate is losing market share in some key markets due to prior underinvestment, which has allowed competitors to gain ground. This underlying structural concern about the company's competitive positioning and future growth prospects likely overshadowed the otherwise positive fiscal Q1 2026 earnings, contributing to the stock's negative trend.
3. High debt load remains a significant investor concern. As of the end of fiscal Q1 2026, Clarivate's total debt outstanding stood at a substantial $4.33 billion. Although the company demonstrated proactive debt management by retiring $143 million of debt during the quarter, supported by $78.9 million in free cash flow, the significant remaining leverage was noted by an equity research analyst as "still high". This elevated debt level could be a deterrent for investors, limiting confidence in the stock.
4. Predominantly cautious to negative analyst sentiment. As of July 1, 2026, Wall Street analysts generally maintained a "Hold" or "Reduce" consensus rating for Clarivate. Out of 8 analysts, 3 had a "Sell" rating, reflecting a cautious outlook for the stock's future performance. This prevailing sentiment among financial professionals likely contributed to downward pressure on the stock price, as the average price target of $3.22, while above the July 1, 2026 price of $2.22, suggests limited conviction for a strong rebound.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -12.3% change in CLVT stock from 3/31/2026 to 7/1/2026 was primarily driven by a -13.8% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7012026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.53 | 2.22 | -12.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,455 | 2,447 | -0.3% |
| P/S Multiple | 0.7 | 0.6 | -13.8% |
| Shares Outstanding (Mil) | 654 | 641 | 2.1% |
| Cumulative Contribution | -12.3% |
Market Drivers
3/31/2026 to 7/1/2026| Return | Correlation | |
|---|---|---|
| CLVT | -12.3% | |
| Market (SPY) | 14.7% | -0.5% |
| Sector (XLK) | 39.7% | 3.5% |
Fundamental Drivers
The -33.5% change in CLVT stock from 12/31/2025 to 7/1/2026 was primarily driven by a -34.9% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7012026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.34 | 2.22 | -33.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,501 | 2,447 | -2.2% |
| P/S Multiple | 0.9 | 0.6 | -34.9% |
| Shares Outstanding (Mil) | 668 | 641 | 4.3% |
| Cumulative Contribution | -33.5% |
Market Drivers
12/31/2025 to 7/1/2026| Return | Correlation | |
|---|---|---|
| CLVT | -33.5% | |
| Market (SPY) | 9.7% | 13.9% |
| Sector (XLK) | 29.1% | 12.2% |
Fundamental Drivers
The -48.4% change in CLVT stock from 6/30/2025 to 7/1/2026 was primarily driven by a -50.4% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7012026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.30 | 2.22 | -48.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,529 | 2,447 | -3.3% |
| P/S Multiple | 1.2 | 0.6 | -50.4% |
| Shares Outstanding (Mil) | 690 | 641 | 7.7% |
| Cumulative Contribution | -48.4% |
Market Drivers
6/30/2025 to 7/1/2026| Return | Correlation | |
|---|---|---|
| CLVT | -48.4% | |
| Market (SPY) | 21.7% | 20.3% |
| Sector (XLK) | 47.2% | 13.4% |
Fundamental Drivers
The -76.7% change in CLVT stock from 6/30/2023 to 7/1/2026 was primarily driven by a -76.3% change in the company's P/S Multiple.| (LTM values as of) | 6302023 | 7012026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.53 | 2.22 | -76.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,627 | 2,447 | -6.8% |
| P/S Multiple | 2.4 | 0.6 | -76.3% |
| Shares Outstanding (Mil) | 675 | 641 | 5.3% |
| Cumulative Contribution | -76.7% |
Market Drivers
6/30/2023 to 7/1/2026| Return | Correlation | |
|---|---|---|
| CLVT | -76.7% | |
| Market (SPY) | 74.2% | 32.4% |
| Sector (XLK) | 117.5% | 25.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CLVT Return | -21% | -65% | 11% | -45% | -34% | -35% | -93% |
| Peers Return | 37% | -20% | 32% | 13% | -12% | -22% | 14% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| CLVT Win Rate | 50% | 25% | 33% | 33% | 42% | 33% | |
| Peers Win Rate | 72% | 38% | 65% | 50% | 48% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CLVT Max Drawdown | -38% | -67% | -47% | -54% | -45% | -52% | |
| Peers Max Drawdown | -12% | -32% | -15% | -13% | -33% | -32% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TRI, SPGI, MCO, VRSK, FDS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/1/2026 (YTD)
How Low Can It Go
| Event | CLVT | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -25.9% | -33.7% |
| % Gain to Breakeven | 35.0% | 50.9% |
| Time to Breakeven | 31 days | 140 days |
In The Past
Clarivate's stock fell -7.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 8.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CLVT | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -25.9% | -33.7% |
| % Gain to Breakeven | 35.0% | 50.9% |
| Time to Breakeven | 31 days | 140 days |
In The Past
Clarivate's stock fell -7.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 8.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Clarivate (CLVT)
Clarivate Plc (CLVT) is an information services and analytics company that provides structured data and tools to help organizations worldwide manage and leverage scientific research, innovations, and brands. Essentially, Clarivate helps its clients navigate the complex landscape of intellectual property, scientific discovery, and brand management by offering critical insights and analytical capabilities.
The company's diverse product portfolio caters to specific needs across different sectors. Its Web of Science suite, including products like EndNote and Journal Citation Reports, supports academic and government institutions in planning and utilizing research. For life sciences companies, products such as Cortellis and Newport Integrity provide crucial intelligence for drug development and market monitoring. Additionally, Clarivate offers Derwent products for intellectual property management, helping businesses evaluate novelty, secure patents, and assess the competitive technology landscape. It also provides CompuMark for trademark services and MarkMonitor to help enterprises manage and protect their online presence.
Clarivate serves a broad global customer base, including government and academic institutions, pharmaceutical and biotechnology companies, and various businesses and law firms that require robust information and analytics for R&D, intellectual property, and brand protection. Its operations are geographically extensive, covering the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, demonstrating its worldwide reach in delivering specialized information solutions.
AI Analysis | Feedback
- It's like S&P Global or FactSet, but for scientific research, intellectual property, and life sciences data instead of financial markets.
- Think of it as Thomson Reuters or LexisNexis, but providing specialized information and tools for academics, scientists, and IP professionals.
- Imagine a Bloomberg Terminal, but for scientists, researchers, and IP professionals to find, analyze, and protect innovations and brands.
AI Analysis | Feedback
- Web of Science: A comprehensive platform for scientific and academic research, discovery, and analysis.
- InCites: An analytics tool used for evaluating research performance and benchmarking.
- Journal Citation Reports: Provides metrics and data for evaluating the impact and performance of scholarly journals.
- EndNote: Software designed for reference management and creating bibliographies.
- ScholarOne: A workflow system facilitating manuscript submission and peer review processes.
- Converis: A research information management system for institutions.
- Publons: A platform that creates researcher profiles and recognizes peer review contributions.
- Kopernio: A tool providing quick and legal access to full-text scholarly articles.
- Cortellis: Provides information and intelligence for pharmaceutical and biotechnology research and market intelligence.
- Newport Integrity: Supports competitive monitoring and intelligence for drug development and commercialization.
- Derwent Innovation: A platform enabling evaluation of product novelty, patent protection, and competitive technology assessment.
- Techstreet: Offers access to industry standards and technical information.
- IP Professional Services: Services related to intellectual property management and strategy.
- CompuMark: Provides trademark screening, searching, and watching services for brand protection.
- MarkMonitor: Helps enterprises manage, optimize, and protect their online presence and digital brands.
AI Analysis | Feedback
Clarivate Plc (CLVT) Major Customers
Clarivate Plc primarily sells its information services and analytics to other companies and institutions, rather than directly to individuals. Based on the provided description, its major customer categories include:- Academic and Government Institutions: These organizations utilize Clarivate's Web of Science products and services for planning, funding, implementing, and utilizing scientific research.
- Life Science Companies: This category primarily includes pharmaceutical and biotechnology companies that use products like Cortellis and Newport Integrity to support research, market intelligence, and competitive monitoring in drug development and commercialization.
- Research and Development Corporations, Businesses, and Law Firms: These customers leverage Derwent, CompuMark, and MarkMonitor products and services for evaluating new products, securing patent protection, assessing competitive technology landscapes, ensuring compliance, trademark screening and protection, and managing their online presence.
AI Analysis | Feedback
null
AI Analysis | Feedback
Matti Shem Tov, Chief Executive Officer
Matti Shem Tov assumed the role of Chief Executive Officer of Clarivate Plc effective August 9, 2024. He brings over 30 years of global leadership experience with deep expertise in software, data, and analytics, as well as in driving innovation and growth. From June 2022 until March 2024, Mr. Shem Tov served as an operating partner at Lone View Capital, a private equity firm, demonstrating a pattern of involvement with private equity-backed entities. Prior to that, he was the Chief Executive Officer of ProQuest LLC from September 2017 to June 2022. Clarivate acquired ProQuest in December 2021, meaning Mr. Shem Tov was involved with a company that was sold to an acquirer.
Jonathan Collins, Executive Vice President and Chief Financial Officer
Jonathan Collins joined Clarivate as Executive Vice President and Chief Financial Officer effective December 16, 2021. Before joining Clarivate, he served as Executive Vice President and CFO of Dana Incorporated from March 2016. Prior to his tenure at Dana, Mr. Collins was Senior Vice President and CFO for ProQuest from 2013 to 2016, and also held the position of Vice President Global Financial Operations at ProQuest from 2010 to 2013.
Bill Graff, Executive Vice President and Chief Information Officer
Maroun S. Mourad, President, Intellectual Property
Bar Veinstein, President, Academia & Government
AI Analysis | Feedback
```html
```
Key Risks to Clarivate's Business
- Competitive Pressures and AI Disruption: Clarivate faces intensifying competitive threats driven by the acceleration of artificial intelligence (AI). AI-driven shifts in user behavior and the emergence of new AI-powered tools from competitors, such as Elsevier's ScienceDirect AI and Scopus AI, are changing the competitive landscape. This could potentially reduce demand for Clarivate's traditional data analytics and research tools and put pressure on its market position and pricing power. The company's advantage in the application layer may become less relevant as AI enables easier access and summarization of information.
- High Leverage and Financial Performance Concerns: Clarivate carries a significant debt load, with its net debt to adjusted EBITDA around 4x, which limits its financial flexibility. The company has reported ongoing net losses and analysts forecast continued losses for 2026, despite a Value Creation Plan aimed at improving financial performance. Should the execution of this plan falter or market conditions deteriorate, Clarivate could face challenges in servicing its debt obligations, potentially impacting its ability to invest in growth or weather economic downturns.
- Dependence on Third-Party Data and Services & Customer Budget Reductions: Clarivate's operations rely on third-party providers for critical data, information, and services. Any disruption in these relationships or a decline in the quality of this data could adversely affect its product offerings and financial performance. Additionally, reductions in research budgets from customers, including government and academic institutions, or decreased funding in key sectors such as pharmaceutical and biotechnology, could negatively impact demand for Clarivate's products and services.
AI Analysis | Feedback
The rapid advancement and adoption of Artificial Intelligence (AI) and Large Language Models (LLMs) present a clear emerging threat to Clarivate's business model. These technologies are enabling new platforms and tools that can significantly enhance or automate various aspects of information discovery, synthesis, and analysis, potentially challenging the value proposition of Clarivate's established, proprietary, and highly curated databases and analytical services.
- For scientific research, AI-powered academic search engines and literature review tools could emerge, offering more intuitive and comprehensive synthesis of research findings across vast data sets. This could potentially reduce the reliance on traditional citation and abstracting databases such as Clarivate's Web of Science and its associated analytical products like InCites and Journal Citation Reports.
- In life sciences, AI-driven platforms are increasingly capable of processing and synthesizing vast amounts of unstructured data from clinical trials, scientific publications, news, and regulatory filings to provide dynamic market intelligence and competitive monitoring. These capabilities could offer alternative or superior insights compared to Clarivate's structured Life Sciences products like Cortellis and Newport Integrity.
- For intellectual property (IP) and brand protection, AI-driven solutions are rapidly developing for tasks such as patent prior art searching, trademark screening, and online brand monitoring. These advancements could offer more efficient, comprehensive, or cost-effective alternatives to Clarivate's Derwent, CompuMark, and MarkMonitor products, potentially disrupting its services for evaluating novelty, securing patent protection, assessing competitive technology landscapes, and protecting online presence.
AI Analysis | Feedback
Clarivate Plc (CLVT) operates in several distinct and addressable markets for its main products and services, as detailed below:
Academic & Government (Web of Science products and services)
- The global Academic Research Databases Market was valued at approximately USD 0.2863 billion in 2024 and is projected to reach USD 0.4919 billion by 2033.
Life Sciences & Healthcare (Cortellis and Newport Integrity)
- The global Life Science Analytics Market was estimated at USD 10.55 billion in 2024 and is projected to reach USD 16.33 billion by 2030. North America accounted for a revenue share of 49.86% in 2024.
- The broader global pharmaceutical market was estimated at approximately $1.77 trillion in 2025, with projections to reach $1.88 trillion by 2026 and nearly $3 trillion by 2034. North America is expected to lead this market, holding a share of 40.3% in 2026.
Intellectual Property (Derwent and CompuMark products)
- The global Intellectual Property Services Market was valued at US$ 4.2 billion in 2024 and is projected to reach US$ 14.3 billion by 2035. North America dominated the market in 2024, holding the largest revenue share of 37.4%.
- The global Patent Analytics Market was valued at USD 1.27 billion in 2024 and is poised to grow to USD 3.84 billion by 2033. North America held a dominant market position in 2023, capturing more than a 35.7% share.
- The global Trademark Services Market was valued at USD 7.11 billion in 2024 and is expected to grow to USD 12 billion by 2035.
Brands (MarkMonitor products)
- The global Digital Risk Protection Platform Market size was estimated at USD 61,242.0 million in 2023 and is projected to reach USD 166,844.1 million by 2030. North America was the largest revenue-generating market in 2023.
- The global Authentication and Brand Protection Market was valued at USD 2.99 billion in 2024 and is projected to grow to USD 7.64 billion by 2032. North America dominated the market with a share of 33.44% in 2024.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Clarivate (CLVT) over the next 2-3 years:
- Transition to a Subscription-Based/Recurring Revenue Model: Clarivate is undergoing a strategic transformation to prioritize recurring revenue streams and subscription-based models. This shift is expected to provide more predictable and stable revenue streams, reducing reliance on volatile transactional revenue. The company's Value Creation Plan (VCP), initiated in late 2024, aims to increase the stability and predictability of its revenue, with analysts projecting recurring revenue to reach approximately 90% by 2027.
- Accelerated Product Innovation and AI-driven Offerings: Clarivate is investing significantly in product innovation and the integration of artificial intelligence (AI) across its portfolio to drive organic growth. These efforts include introducing new products and AI-powered features designed to meet evolving customer needs, enhance customer workflows, and improve the quality of insights. An example of this is the launch of Clarivate Nexus, an AI-integrated academic assistant.
- Enhanced Sales Execution and Customer Retention: The company plans to boost sales and customer retention by investing in its sales team, improving sales strategies, and enhancing customer engagement. Clarivate reported stable revenue retention rates of 93% in 2025 and is strategically focused on improving client retention and promoting upselling opportunities.
- Organic Annual Contract Value (ACV) Growth: Clarivate is targeting 2% to 3% organic Annual Contract Value (ACV) growth for 2026, building on nearly 2% organic ACV growth achieved in 2025. This growth is driven by new customer acquisitions and the expansion of existing contracts within its core markets.
- Strategic Portfolio Optimization: The planned divestiture of its Life Sciences & Health segment is a strategic move to sharpen Clarivate's focus on its core markets and proprietary solutions. This portfolio optimization is anticipated to lead to improved operational efficiency, enhanced profitability, and an increased focus on high-value, proprietary assets, despite potentially lower reported revenue in the near term.
AI Analysis | Feedback
Share Repurchases
- Clarivate repurchased $100 million of ordinary shares in 2023 and $200 million in 2024.
- The company repurchased approximately $225 million in ordinary shares, totaling 56.0 million shares, in 2025.
- A new share repurchase program of up to $500 million was authorized from January 1, 2025, through December 31, 2026.
Share Issuance
- Clarivate converted all outstanding mandatory convertible preferred shares into ordinary shares, which eliminated future dividend obligations on these shares.
- The number of ordinary shares outstanding decreased from approximately 674.4 million as of January 31, 2023, to 640.7 million as of December 31, 2025.
Outbound Investments
- Clarivate divested its MarkMonitor business in late 2022.
- In 2024, the company divested its ScholarOne and Valipat businesses to simplify operations.
- Clarivate is currently pursuing a sale of its Life Sciences & Healthcare business and is engaged in active discussions with interested parties.
Capital Expenditures
- Clarivate's capital expenditures were estimated to be approximately $255 million during 2025.
- The primary focus of these expenditures is for product and content development, as well as ongoing support of existing business operations.
- Disciplined capital spending contributed to an increase in free cash flow to $365.3 million in 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| CLVT Dip Buy Analysis | 07/10/2025 | |
| Clarivate (CLVT) Valuation Ratios Comparison | 05/15/2025 | |
| Clarivate Total Shareholder Return (TSR): -45.1% in 2024 and -40.0% 3-yr compounded annual returns (below peer average) | 03/07/2025 | |
| null | 12/15/2024 | |
| Day 5 of Gains Streak for Clarivate Stock with 32% Return (vs. -38% YTD) [11/25/2024] | 11/25/2024 | |
| Clarivate Market Price | 11/25/2024 | |
| Day 5 of Gains Streak for Clarivate Stock with 32% Return (vs. -38% YTD) [11/23/2024] | 11/23/2024 | |
| Clarivate vs. S&P500 Correlation | 10/03/2024 | |
| Clarivate Price Volatility | 09/24/2024 | |
| Fundamental Metrics: ... | 06/19/2024 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 214.63 |
| Mkt Cap | 31.0 |
| Rev LTM | 5,383 |
| Op Inc LTM | 1,712 |
| FCF LTM | 1,600 |
| FCF 3Y Avg | 1,474 |
| CFO LTM | 2,046 |
| CFO 3Y Avg | 1,891 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.2% |
| Rev Chg 3Y Avg | 6.8% |
| Rev Chg Q | 7.6% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Inc Chg LTM | 7.5% |
| Op Inc Chg 3Y Avg | 7.3% |
| Op Mgn LTM | 36.0% |
| Op Mgn 3Y Avg | 34.5% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 35.9% |
| CFO/Rev 3Y Avg | 35.5% |
| FCF/Rev LTM | 31.7% |
| FCF/Rev 3Y Avg | 30.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Academia and Government | 1,266 | 1,326 | 1,323 | 1,280 | 489 |
| Intellectual Property | 799 | 811 | 863 | 927 | 978 |
| Life Sciences and Healthcare | 390 | 419 | 443 | 453 | 413 |
| Deferred revenues adjustment | -4 | ||||
| Total | 2,455 | 2,557 | 2,629 | 2,660 | 1,877 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Academia and Government | 548 | 564 |
| Intellectual Property | 334 | 358 |
| Life Sciences and Healthcare | 120 | 138 |
| Goodwill and intangible asset impairments | -15 | -541 |
| Other | -22 | 30 |
| Transaction related costs | -22 | -18 |
| Restructuring costs | -51 | -20 |
| Share-based compensation expense | -63 | -61 |
| Depreciation and amortization | -757 | -727 |
| Total | 72 | -276 |
Price Behavior
Price Behavior
| Market Price | $2.22 | |
| Market Cap ($ Bil) | 1.4 | |
| First Trading Date | 10/29/2018 | |
| Distance from 52W High | -51.0% | |
| 50 Days | 200 Days | |
| DMA Price | $2.44 | $2.92 |
| DMA Trend | down | down |
| Distance from DMA | -9.0% | -24.1% |
| 3M | 1YR | |
| Volatility | 64.9% | 67.8% |
| Downside Capture | 19.33 | 198.01 |
| Upside Capture | -31.77 | 67.61 |
| Correlation (SPY) | -0.3% | 20.2% |
CLVT Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.46 | 0.14 | 0.24 | 0.87 | 1.10 | 1.25 |
| Up Beta | -1.56 | -0.84 | -0.31 | 0.01 | 0.50 | 1.18 |
| Down Beta | 1.31 | 1.12 | 1.97 | 1.25 | 1.18 | 1.29 |
| Up Capture | -19% | -80% | -16% | 37% | 58% | 58% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 9 | 18 | 29 | 51 | 113 | 339 |
| Down Capture | 144% | 106% | 40% | 151% | 150% | 110% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 12 | 23 | 33 | 69 | 129 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CLVT | |
|---|---|---|---|---|
| CLVT | -47.9% | 68.0% | -0.70 | - |
| Sector ETF (XLK) | 47.4% | 23.9% | 1.56 | 13.3% |
| Equity (SPY) | 21.8% | 12.5% | 1.30 | 20.3% |
| Gold (GLD) | 21.7% | 27.7% | 0.69 | -13.4% |
| Commodities (DBC) | 21.4% | 18.6% | 0.90 | -0.9% |
| Real Estate (VNQ) | 13.0% | 13.7% | 0.65 | 16.3% |
| Bitcoin (BTCUSD) | -45.0% | 42.6% | -1.28 | 10.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CLVT | |
|---|---|---|---|---|
| CLVT | -38.6% | 55.1% | -0.68 | - |
| Sector ETF (XLK) | 21.7% | 25.4% | 0.76 | 35.2% |
| Equity (SPY) | 13.5% | 17.1% | 0.61 | 40.9% |
| Gold (GLD) | 17.4% | 18.3% | 0.77 | 0.9% |
| Commodities (DBC) | 6.8% | 19.5% | 0.25 | 4.9% |
| Real Estate (VNQ) | 2.8% | 18.8% | 0.05 | 38.8% |
| Bitcoin (BTCUSD) | 11.9% | 53.7% | 0.41 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CLVT | |
|---|---|---|---|---|
| CLVT | -13.5% | 50.8% | -0.18 | - |
| Sector ETF (XLK) | 25.2% | 24.8% | 0.92 | 36.1% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 39.3% |
| Gold (GLD) | 11.9% | 16.1% | 0.60 | 5.0% |
| Commodities (DBC) | 5.6% | 18.0% | 0.24 | 9.2% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 36.0% |
| Bitcoin (BTCUSD) | 56.6% | 66.3% | 0.97 | 14.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/29/2026 | 13.9% | 10.4% | 1.6% |
| 2/24/2026 | 39.9% | 37.5% | 47.0% |
| 10/29/2025 | -4.1% | -4.4% | 3.0% |
| 7/30/2025 | -4.3% | -12.8% | 5.9% |
| 4/29/2025 | 17.3% | 19.2% | 17.8% |
| 2/19/2025 | -1.4% | -7.5% | -9.1% |
| 11/6/2024 | -27.2% | -30.3% | -13.4% |
| 8/6/2024 | -12.2% | -10.4% | 9.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 13 |
| # Negative | 15 | 13 | 11 |
| Median Positive | 12.7% | 7.3% | 9.8% |
| Median Negative | -7.8% | -7.5% | -13.4% |
| Max Positive | 39.9% | 37.5% | 47.0% |
| Max Negative | -27.2% | -30.3% | -17.9% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/29/2026 | 13.9% | 10.4% | 1.6% |
| 2/24/2026 | 39.9% | 37.5% | 47.0% |
| 10/29/2025 | -4.1% | -4.4% | 3.0% |
| 7/30/2025 | -4.3% | -12.8% | 5.9% |
| 4/29/2025 | 17.3% | 19.2% | 17.8% |
| 2/19/2025 | -1.4% | -7.5% | -9.1% |
| 11/6/2024 | -27.2% | -30.3% | -13.4% |
| 8/6/2024 | -12.2% | -10.4% | 9.8% |
| 5/8/2024 | -11.4% | -6.2% | -17.1% |
| 2/27/2024 | -17.4% | -21.0% | -17.9% |
| 11/7/2023 | 3.0% | -4.0% | 17.3% |
| 8/3/2023 | -22.3% | -21.5% | -17.3% |
| 5/9/2023 | 3.6% | 8.9% | 12.0% |
| 3/1/2023 | 12.7% | 7.1% | -8.1% |
| 11/8/2022 | -3.0% | 1.6% | -9.8% |
| 8/9/2022 | -11.0% | -5.8% | -15.5% |
| 5/9/2022 | -1.1% | -2.0% | 2.6% |
| 3/10/2022 | 12.8% | 17.2% | 29.0% |
| 10/28/2021 | 3.7% | 7.3% | 4.4% |
| 7/29/2021 | -7.8% | -1.1% | 3.3% |
| 4/29/2021 | 3.1% | 5.3% | 11.0% |
| 2/25/2021 | -15.9% | -21.0% | -14.6% |
| 10/29/2020 | -6.1% | 0.9% | -8.4% |
| 7/30/2020 | -3.7% | 3.3% | -2.0% |
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 13 |
| # Negative | 15 | 13 | 11 |
| Median Positive | 12.7% | 7.3% | 9.8% |
| Median Negative | -7.8% | -7.5% | -13.4% |
| Max Positive | 39.9% | 37.5% | 47.0% |
| Max Negative | -27.2% | -30.3% | -17.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/29/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/19/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/29/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/19/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 03/10/2022 | 10-K |
| 09/30/2021 | 10/28/2021 | 10-Q |
| 06/30/2021 | 07/29/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 02/26/2021 | 10-K |
| 09/30/2020 | 10/29/2020 | 10-Q |
| 06/30/2020 | 07/30/2020 | 10-Q |
| 03/31/2020 | 05/04/2020 | 10-Q |
| 12/31/2019 | 03/02/2020 | 10-K |
| 09/30/2019 | 11/05/2019 | 6-K |
| 06/30/2019 | 08/07/2019 | 6-K |
Recent Forward Guidance
Updated 5/31/2026Latest: Q1 2026 Earnings Reported 4/29/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Organic ACV | 0.02 | 0.03 | 0.03 | 0 | 0 | Affirmed | Guidance: 0.03 for 2026 |
| 2026 Revenue | 2.30 Bil | 2.36 Bil | 2.42 Bil | 0 | Affirmed | Guidance: 2.36 Bil for 2026 | |
| 2026 Adjusted EBITDA | 980.00 Mil | 1.01 Bil | 1.04 Bil | 0 | Affirmed | Guidance: 1.01 Bil for 2026 | |
| 2026 Adjusted EBITDA Margin | 42.0% | 42.75% | 43.5% | 0 | 0 | Affirmed | Guidance: 42.75% for 2026 |
| 2026 Adjusted Diluted EPS | 0.7 | 0.75 | 0.8 | 0 | Affirmed | Guidance: 0.75 for 2026 | |
| 2026 Free Cash Flow | 365.00 Mil | 400.00 Mil | 435.00 Mil | 0 | Affirmed | Guidance: 400.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/24/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Organic ACV | 0.02 | 0.03 | 0.03 | 66.7% | 1.0% | Higher New | Actual: 0.01 for 2025 |
| 2026 Recurring Organic Revenue Growth | 0.75% | 1.5% | 2.25% | 1.5% | Higher New | Actual: 0.0% for 2025 | |
| 2026 Revenue | 2.30 Bil | 2.36 Bil | 2.42 Bil | -3.1% | Lower New | Actual: 2.44 Bil for 2025 | |
| 2026 Adjusted EBITDA | 980.00 Mil | 1.01 Bil | 1.04 Bil | 4.1% | Higher New | Actual: 970.00 Mil for 2025 | |
| 2026 Adjusted EBITDA Margin | 42.0% | 42.75% | 43.5% | 3.0% | 1.2% | Higher New | Actual: 41.5% for 2025 |
| 2026 Adjusted Diluted EPS | 0.7 | 0.75 | 0.8 | 15.4% | Higher New | Actual: 0.65 for 2025 | |
| 2026 Free Cash Flow | 365.00 Mil | 400.00 Mil | 435.00 Mil | 17.6% | Higher New | Actual: 340.00 Mil for 2025 | |
Insider Activity
Updated 6/16/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Veinstein, Bar | President, A&G | Direct | Sell | 12022025 | 3.74 | 309,902 | 1,159,033 | 3,174,553 | Form |
| 2 | Cornick, Kenneth L | Cornick Family Investor, LLC | Buy | 11032025 | 3.52 | 225,000 | 792,000 | 3,520,000 | Form | |
| 3 | Cornick, Kenneth L | Cornick Family Investor, LLC | Buy | 11032025 | 3.38 | 500,000 | 1,690,000 | 2,619,500 | Form | |
| 4 | Snyder, Andrew Miles | Cambridge Information Group I LLC | Buy | 11032025 | 3.33 | 1,460,000 | 4,861,800 | 7,484,208 | Form | |
| 5 | Cornick, Kenneth L | Cornick Family Investor, LLC | Buy | 8052025 | 3.74 | 165,000 | 617,100 | 1,028,500 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Veinstein, Bar | President, A&G | Direct | Sell | 12022025 | 3.74 | 309,902 | 1,159,033 | 3,174,553 | Form |
| 2 | Cornick, Kenneth L | Cornick Family Investor, LLC | Buy | 11032025 | 3.52 | 225,000 | 792,000 | 3,520,000 | Form | |
| 3 | Cornick, Kenneth L | Cornick Family Investor, LLC | Buy | 11032025 | 3.38 | 500,000 | 1,690,000 | 2,619,500 | Form | |
| 4 | Snyder, Andrew Miles | Cambridge Information Group I LLC | Buy | 11032025 | 3.33 | 1,460,000 | 4,861,800 | 7,484,208 | Form | |
| 5 | Cornick, Kenneth L | Cornick Family Investor, LLC | Buy | 8052025 | 3.74 | 165,000 | 617,100 | 1,028,500 | Form | |
| 6 | Samson, James Gordon | President, IP | Direct | Sell | 7022025 | 4.53 | 100,000 | 453,000 | 5,758,097 | Form |
Clarivate — Investor Video Playlist
Products & Services
3 ways that the AI-powered Web of Science Research Assistant helps you research more efficiently
Products & Services
One partner transforming the way you create, manage and protect intellectual property
Products & Services
Deliver safe, effective and commercially successful treatments to patients faster
Industry Resources
| Information Technology Resources |
| TechCrunch |
| Wired |
| CIO |
| MIT Technology Review |
| Gartner Insights |
| Ars Technica |
| IT Consulting & Other Services Resources |
| IDC |
| Forrester |
| Consultancy.org |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/1/2026